Tempus AI (NASDAQ:TEM) EVP Andrew Polovin Sells 2,951 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 2,951 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $221,325.00. Following the transaction, the executive vice president owned 135,189 shares in the company, valued at approximately $10,139,175. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The shares were sold at an average price of $56.00, for a total value of $443,912.00.
• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28.

Tempus AI Stock Down 3.1%

Shares of NASDAQ TEM opened at $77.84 on Friday. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The stock has a market capitalization of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72. The stock’s fifty day moving average is $57.19 and its 200 day moving average is $52.90.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. Sell-side analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a research note on Wednesday, September 2nd. HC Wainwright upped their target price on Tempus AI from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. UBS Group assumed coverage on Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price on the stock. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 11th. Finally, Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $69.33.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently made changes to their positions in the stock. EMC Capital Management bought a new stake in shares of Tempus AI during the 2nd quarter valued at approximately $29,000. Whittier Trust Co. lifted its stake in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the last quarter. CoreCap Advisors LLC lifted its stake in Tempus AI by 293.4% in the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares during the last quarter. Global Assets Advisory LLC acquired a new stake in Tempus AI in the first quarter valued at approximately $46,000. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Tempus AI in the fourth quarter valued at approximately $70,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.